Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anna Carbó Bagué"'
Autor:
María Jesús Rubio, Aránzazu Manzano, Luis Miguel de Sande, Purificación Estévez-García, María del Mar Gordon, Diego Soto de Prado, Blanca Hernando Fernández de Aranguiz, Eva M. Guerra-Alia, Anna Carbó-Bagué, Ignacio Romero, Miguel Corbellas, Alba González-Haba, Carlos E. Robles-Barraza, Jerónimo Martínez-García, Antonio González-Martín
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is approved for the treatment of patients with platinum-sensitive relapsed ovarian cancer. Nevertheless, there is currently limited information regarding this t
Externí odkaz:
https://doaj.org/article/39144675c87243c3ade5b788dbad20d1
Autor:
Anna Carbó-Bagué, Laura Cerón-Nasarre, Laia Valls-Masot, Cristina Melendez-Munoz, Elisabet Bujons-Buscarons, Raquel Liñan-Planas, Maria Pilar Barretina-Ginesta
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 1436-1442 (2023)
Introduction: Esophageal involvement in high-grade serous ovarian carcinoma is a rare phenomenon when advanced systemic disease is detected. Dysphagia is the most common guide symptom. However, diagnosis is often delayed due to its submucosal process
Externí odkaz:
https://doaj.org/article/1a477540d6144d1596660332f0025459
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1289-1294 (2021)
Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a c
Externí odkaz:
https://doaj.org/article/04e043ef3acc461e8ecaf4d8bc5482aa
Autor:
Laura Cárdenas Puiggrós, Pedro Alberto Corzo Orantos, Isabel Núñez Márquez, Anna Taltavull Pons, Cristina Meléndez Muñoz, Anna Carbó Bagué, Hugo Javier Rosales González, Eduard Sala Hernández, Elena Álvarez Castaño
Publikováno v:
Endometrial cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72a4379bb0873bd7845d1de59c06e2dc
https://doi.org/10.1136/ijgc-2022-esgo.314
https://doi.org/10.1136/ijgc-2022-esgo.314
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1289-1294 (2021)
Case Reports in Oncology, 2021, vol. 14, núm. 3
Articles publicats (IdIBGi)
Anna Carbó-Bagué Roser Fort-Culillas Helena Pla-Juher Rubió Casadevall, Jordi 2021 Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report Case Reports in Oncology 14 3
DUGiDocs – Universitat de Girona
instname
Case Reports in Oncology
Carbó-Bagué, Anna Fort-Culillas, Roser Pla-Juher, Helena Rubió Casadevall, Jordi 2021 Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report. Case Reports in Oncology 14 3
Case Reports in Oncology, 2021, vol. 14, núm. 3
Articles publicats (IdIBGi)
Anna Carbó-Bagué Roser Fort-Culillas Helena Pla-Juher Rubió Casadevall, Jordi 2021 Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report Case Reports in Oncology 14 3
DUGiDocs – Universitat de Girona
instname
Case Reports in Oncology
Carbó-Bagué, Anna Fort-Culillas, Roser Pla-Juher, Helena Rubió Casadevall, Jordi 2021 Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report. Case Reports in Oncology 14 3
Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6abfec7668f58b157b80537dd3a4708b
https://doi.org/10.1159/000518530
https://doi.org/10.1159/000518530
Autor:
Anna Carbó-Bagué, Jordi Rubió-Casadevall, Montserrat Puigdemont, Arantza Sanvisens, Glòria Oliveras, Mònica Coll, Bernat del Olmo, Ferran Perez-Bueno, Rafael Marcos-Gragera
Publikováno v:
Cancers, Vol 14, Iss 780, p 780 (2022)
Cancers, 2022, vol. 14, núm. 3, p. 780
Articles publicats (D-CM)
Carbó-Bagué, Anna Rubió Casadevall, Jordi Puigdemont, Montserrat Sanvisens, Arantza Oliveras, Glòria Coll, Mónica Olmo, Bernat del Perez Bueno, Ferran Marcos Gragera, Rafael 2022 Epidemiology and Molecular Profile of Mucosal Melanoma: A Population-Based Study in Southern Europe Cancers 14 3 780
DUGiDocs – Universitat de Girona
instname
Cancers; Volume 14; Issue 3; Pages: 780
Cancers, 2022, vol. 14, núm. 3, p. 780
Articles publicats (D-CM)
Carbó-Bagué, Anna Rubió Casadevall, Jordi Puigdemont, Montserrat Sanvisens, Arantza Oliveras, Glòria Coll, Mónica Olmo, Bernat del Perez Bueno, Ferran Marcos Gragera, Rafael 2022 Epidemiology and Molecular Profile of Mucosal Melanoma: A Population-Based Study in Southern Europe Cancers 14 3 780
DUGiDocs – Universitat de Girona
instname
Cancers; Volume 14; Issue 3; Pages: 780
Background: Mucosal melanoma is a rare neoplasm on which few epidemiological population-based studies have been published. A good surgical approach is the standard treatment, but the prognosis is worse than that of skin melanoma. The analysis of muco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29e38d71a31282e6f007afbe63eeb56f
https://www.mdpi.com/2072-6694/14/3/780
https://www.mdpi.com/2072-6694/14/3/780
Autor:
Rafael Marcos-Gragera, Ferran Martín-Romero, Gemma Osca-Gelis, Montserrat Llobet-Roma, Neus Vilar-Coromina, Anna Carbó-Bagué, Ferran Pérez-Bueno, Antoni Urban, Berta Ferrer-Fabrega, Montserrat Puigdemont, Glòria Oliveras, Jordi Rubió-Casadevall
Publikováno v:
European journal of dermatology : EJD. 31(5)
The prevalence of BRAF mutation has been reported in between 38% and 48% of melanoma patients, based on mainly Stage III or metastatic melanoma, however, information based on population-based studies is scarce. We performed a population-based retrosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b6982f845d2a4ad84222677e6be5d1c
https://pubmed.ncbi.nlm.nih.gov/34789445
https://pubmed.ncbi.nlm.nih.gov/34789445